Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta‐analyses and forecasting study
- 8 September 2023
- journal article
- review article
- Published by Wiley in Acta Ophthalmologica
- Vol. 101 (8) , 857-868
Abstract
We systematically reviewed the literature on the prevalence of geographic atrophy (GA) in Nordic populations, conducted meta-analyses on age-stratified estimates, and calculated current and future number of patients and those potentially eligible for intravitreal complement inhibitor treatment. We followed the PRISMA guidelines, and our protocol was registered in PROSPERO. Ten databases were searched on 22 April 2023 for population-based studies of GA prevalence. Based on clinical descriptive analyses of GA and eligibility criteria of the phase III studies for intravitreal pegcetacoplan (complement C3 and C3b inhibitor), we were able to calculate the proportion of patients with GA potentially eligible for therapy. Finally, we extracted population data for Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) from Eurostat, applied prevalence statistics to the extracted census and forecasting data to estimate the number of patients with GA, and then applied the proportion eligible for intravitreal pegcetacoplan therapy. We identified six studies with a total of 10 159 individuals. Prevalence of GA was estimated to 0.4% (95% confidence intervals [CI]: 0.2%-0.8%), 1.5% (95% CI: 0.7%-2.6%), and 7.6% (95% CI: 4.6%-11.3%) for individuals aged 60-69, 70-79, and 80+ years, respectively. In Nordic countries, we estimate a total of 166 307 individuals with GA in 2023, increasing to 277 893 in 2050. Of these, 90 803 individuals in 2023, increasing to 151 730 in 2050, are potentially eligible for intravitreal complement inhibitor treatment. Considering these large numbers, our study highlights the importance of this topic in the coming years and its potential to significantly impact our clinical practice, organization, and staffing.Keywords
This publication has 40 references indexed in Scilit:
- The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta‐analysis, and clinical practice guideline: a systematic reviewJournal of Evidence-Based Medicine, 2015
- Meta-analysis of prevalenceJournal of Epidemiology and Community Health, 2013
- Prevalence of Age-related Macular Degeneration in Elderly Caucasians: The Tromsø Eye StudyOphthalmology, 2012
- Projected prevalence of age‐related macular degeneration in Scandinavia 2012–2040Acta Ophthalmologica, 2012
- Prevalence of Age-related Macular Degeneration in Old Persons: Age, Gene/Environment Susceptibility Reykjavik StudyOphthalmology, 2011
- Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical JournalsJAMA, 2007
- Progression of Geographic Atrophy and Impact of Fundus Autofluorescence Patterns in Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- The prevalence of age‐related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular StudyActa Ophthalmologica Scandinavica, 2006
- Risk factors for age‐related maculopathy in a 14‐year follow‐up study: the Copenhagen City Eye StudyActa Ophthalmologica Scandinavica, 2005
- The Prevalence of Age-Related Maculopathy in IcelandArchives of Ophthalmology (1950), 2003